Importantly, combining SRSF1 inactivation in tumor cells with PD-1 blockade significantly improved survival in B16F10 melanoma, Hep1-6 subcutaneous tumors, and CTNNB1N90; Trp53KO autochthonous murine HCC models. The gene discussed is SRSF1; the disease is neoplasm.